Health & Biotech

Dr Boreham’s Crucible: Avita in for a busy 2020 with big expansion ambitions

December 22, 2019December 22, 2019 | Tim Boreham

Health & Biotech

Health Kick Podcast: Commercialising orphan drugs, the need for better regulation and the ASX’s lifestyle play problem

December 18, 2019January 24, 2020 | Tim Boreham

Health & Biotech

Dr Boreham’s Crucible: MedAdvisor could cure what ails it by shelving its expansion plans

December 15, 2019December 15, 2019 | Tim Boreham

Health & Biotech

Health Kick Podcast: The science behind 2019’s hottest IPO and the company’s plans for 2020

December 11, 2019January 24, 2020 | Tim Boreham

Health & Biotech

Dr Boreham’s Crucible: Memphasys now feeling the investor love for its IVF tech

December 8, 2019December 8, 2019 | Tim Boreham

Health & Biotech

Health Kick Podcast: Investing in repurposed drugs, combating intracranial pressure and why Invex caught NASA’s eye

December 4, 2019January 24, 2020 | Tim Boreham

Health & Biotech

Dr Boreham’s Crucible: Visioneering is flexing its muscles as it vies for a share of the $US2bn kids contact lens market

December 1, 2019December 7, 2019 | Tim Boreham

Health & Biotech

Health Kick Podcast: What’s holding back better breast cancer detection? And how is Volpara’s tech changing the game?

November 27, 2019January 24, 2020 | Tim Boreham

Health & Biotech

Dr Boreham’s Crucible: Can Phylogica finally make magic happen after nearly 15 years of trying?

November 24, 2019December 7, 2019 | Tim Boreham

Health & Biotech

Health Kick Podcast: Developing drugs, fighting fibrosis and squeezing squishometers

November 20, 2019January 24, 2020 | Tim Boreham

Health & Biotech

Dr Boreham’s Crucible: Uscom gets an A+ for everything but its share price

November 17, 2019November 17, 2019 | Tim Boreham

Health & Biotech

Health Kick Podcast: How Aussie health stocks are performing internationally and Prescient’s cancer-blocking innovation

November 13, 2019January 24, 2020 | Tim Boreham